B. Riley analyst Yuan Zhi downgraded Fusion Pharmaceuticals (FUSN) to Neutral from Buy with a price target of $23, up from $13. Based on existing collaboration on Ac225-labelled bispecifics, B. Riley believes Fusion’s FPI-2265 fits nicely in AstraZeneca’s (AZN) prostate cancer franchise, the analyst tells investors in a research note, adding that Fusion shares are being acquired in a fair value range.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FUSN:
- UK Stocks: AstraZeneca (AZN) Expands Cancer Portfolio with Fusion Pharma Acquisition
- Fusion Pharmaceuticals’ Acquisition and Future Focus Shift
- Fusion Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
- Fusion Pharmaceuticals to be acquired by AstraZeneca in $2.4B transaction
- Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
